CTLA4 and gastric cancer: To further validate the role of HA during immune checkpoint blockade (ICB) treatment, biomarker data were analyzed from two independent cohorts: (i) patients with metastatic GC who were treated with pembrolizumab monotherapy; and (ii) patients with GI cancers treated with anti-PD(L)-1 and/or anti-CTLA-4 antibodies.